Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
Translational Andrology and Urology
|
September 18, 2020
Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype
Brendan Connell, Pavel Kopach, Wenying Ren, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm
Edwin Wang, Jessica K Paulus, Douglas Hackenyos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
Shi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
Annals of Internal Medicine
|
February 22, 2012
Active surveillance in men with localized prostate cancer: a systematic review
Issa J Dahabreh, Mei Chung, Ethan M Balk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 2, 2013
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study
Paul G Corn, Danny Y Song, Elisabeth Heath, et al.
The American Journal of Sports Medicine
|
August 21, 2024
Cryo-Pneumatic Compression Results in a Significant Decrease in Opioid Consumption After Shoulder Surgery: A Multicenter Randomized Controlled Trial
Moin Khan, Steven A Phillips, Paul Mathew, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2011
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib
Paul Mathew, Nizar Tannir, Shi-Ming Tu, et al.
Cancer Research
|
May 4, 2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
Sun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
Molecular Cancer Research : MCR
|
June 23, 2025
A novel bispecific integrin α5β1/αv antibody reprograms the Myc-regulated basal phenotype of prostate cancer with natural killer cell-mediated tumor elimination
Raghav Joshi, Ming Zhou, Jeffrey H Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
Paul Mathew, Peter F Thall, Donnah Jones, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
Translational Andrology and Urology
|
September 18, 2020
Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype
Brendan Connell, Pavel Kopach, Wenying Ren, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm
Edwin Wang, Jessica K Paulus, Douglas Hackenyos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
Shi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
Annals of Internal Medicine
|
February 22, 2012
Active surveillance in men with localized prostate cancer: a systematic review
Issa J Dahabreh, Mei Chung, Ethan M Balk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 2, 2013
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study
Paul G Corn, Danny Y Song, Elisabeth Heath, et al.
The American Journal of Sports Medicine
|
August 21, 2024
Cryo-Pneumatic Compression Results in a Significant Decrease in Opioid Consumption After Shoulder Surgery: A Multicenter Randomized Controlled Trial
Moin Khan, Steven A Phillips, Paul Mathew, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2011
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib
Paul Mathew, Nizar Tannir, Shi-Ming Tu, et al.
Cancer Research
|
May 4, 2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
Sun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
Molecular Cancer Research : MCR
|
June 23, 2025
A novel bispecific integrin α5β1/αv antibody reprograms the Myc-regulated basal phenotype of prostate cancer with natural killer cell-mediated tumor elimination
Raghav Joshi, Ming Zhou, Jeffrey H Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
Paul Mathew, Peter F Thall, Donnah Jones, et al.
Page
of 7